Skip to main navigation Skip to search Skip to main content

Congenital sacrococcygeal PNET and chemotherapy

Research output: Contribution to journalArticlepeer-review

Abstract

We present the case of a congenital localised sacrococcygeal primitive neuroectodermal tumor treated aggressively with surgical resection and modified age-appropriate adjuvant chemotherapy. The conventional combination chemotherapy of vincristine, adriamycin, cyclophosphamide, ifosfamide and etoposide was modified to a regimen including vincristine, adriamicin, cyclophosphamide and actinomycin in order to minimise the predicted toxicity in this age group. Adjuvant "induction" chemotherapy commenced at 4 weeks of age and consisted of four cycles of vincristine, adriamycin and cyclophosphamide at 50%, 75%, 75% and 100% of recommended doses (vincristine 0.05 mg/kg, adriamycin 0.83 mg/kg daily 2, cyclophosphamide 40 mg/kg) at 3-weekly intervals. This was followed by four cycles of "maintenance" chemotherapy with vincristine (0.025 mg/kg), actinomycin (0.025 mg/kg) and cyclophosphamide (36 mg/kg) at full recommended doses. Cardioxane at a dose of 16.6 mg/kg was infused immediately prior to the adriamycin. Our patient is thriving at 19 months out from end of treatment.

Original languageEnglish
Pages (from-to)182-184
Number of pages3
JournalIndian Journal of Medical and Paediatric Oncology
Volume33
Issue number3
DOIs
Publication statusPublished - 2012
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Chemotherapy
  • Neonatal
  • Peripheral primitive neuroectodermal tumor
  • Primitive neuroectodermal tumor

Fingerprint

Dive into the research topics of 'Congenital sacrococcygeal PNET and chemotherapy'. Together they form a unique fingerprint.

Cite this